CCL7/MCP-3/MARC Antibody from R&D Systems, a Bio-Techne Brand

The CCL7/MCP-3/MARC antibody has been shown to work in applications such as Western blotting, flow cytometry, and immunofluorescence. It has been utilized in studies investigating the role of CCL7 in monocyte recruitment during lung ischemia/reperfusion injury and in the context of inflammatory bowel diseases, where it contributes to macrophage polarization and intestinal inflammation.

The antibody specifically detects mouse CCL7/MCP-3/MARC in direct ELISAs and Western blots, with approximately 15% cross-reactivity with recombinant human Eotaxin and recombinant mouse JE, and less than 5% cross-reactivity with recombinant mouse MCP-5.

Yes, studies have reported that CCL7 plays a significant role in recruiting classical monocytes to injured tissues, such as in lung injury models. For instance, B cells have been shown to produce CCL7, which is critical for monocyte recruitment and subsequent neutrophil extravasation, leading to worsened lung function after ischemia/reperfusion injury.

CCL7 has been implicated in promoting macrophage infiltration and polarization towards a pro-inflammatory phenotype, particularly in conditions such as abdominal aortic aneurysm and myocardial infarction. The antibody has been used to neutralize CCL7 in various studies, demonstrating its role in modulating immune responses and tissue repair processes.